[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuropsychological-tests\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuropsychological-tests":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,75,96,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100602388","predictive-factors-for-initial-mmse-score-and-rapid-decline-in-alzheimers-disease-patients-100602388",false,"NCT07122856","Predictive Factors for Initial MMSE Score and Rapid Decline in Alzheimer's Disease Patients","Inclusion Criteria:\n\n* Confirmed diagnosis of Alzheimer's disease according to NIAA 2018 or IWG 2021 criteria\n* At least two MMSE evaluations spaced 12 months apart\n* Follow-up at the Memory Clinic of CH Gonesse\n\nExclusion Criteria:\n\n* Presence of other neurodegenerative diseases (e.g., Frontotemporal Dementia, Multiple System Atrophy, Vascular Dementia, LATE)\n* Patient has moved out of the study area (outside the CH Gonesse territory)","ALL",{"count":17,"type":18},100,"ESTIMATED","OBSERVATIONAL","This study looks at people with Alzheimer's disease to find out which factors are linked to their initial score on the Mini-Mental State Examination (MMSE) and which factors may predict a fast decline in their score over 12 months. Researchers will review medical records from patients seen at the Memory Clinic of Gonesse Hospital and analyze information such as age, education, medical history, nutrition, mood, and caregiver burden. The goal is to better understand what influences early cognitive performance and how quickly it changes, to help improve patient care and planning.",[22,23,24,25,26],"Alzheimer Disease","Mini-Mental State Examination","Cognitive Dysfunction","Neuropsychological Tests","Caregivers","NOT_YET_RECRUITING","2025-08-08",{"date":30,"type":31},"2025-08-14","ACTUAL",{"date":33,"type":18},"2025-09-15",{"date":35,"type":18},"2026-03-15",{"name":37,"class":38},"Centre Hospitalier de Gonesse","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":50,"conditions":51,"keywords":57,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":39},"100467852","vanderbilt-memory-and-aging-project-100467852","NCT05372159","Vanderbilt Memory and Aging Project","VMAP","Inclusion Criteria:\n\n* Participants recruited will include 1,000 adults age 50 and older.\n* After the eligibility visit, a small portion of participants (\\~150) enrolling must meet diagnostic criteria for mild cognitive impairment according to a clinician diagnosis and\u002For medical records (i.e., participants must have mild memory or cognitive problems, but they must be free of any functional problems and not have Alzheimer's disease or another form of dementia). The remaining \\~850 participants will be cognitively unimpaired adults age 50 and older.\n* Because the neuropsychological tests used to measure cognitive performance are validated on English-speaking populations, we require that English be the primary language of all participants.\n\nExclusion Criteria:\n\n* No available reliable study partner\n* History of major psychiatric illness (e.g., schizophrenia, bipolar), neurological illness (e.g., stroke, epilepsy, multiple sclerosis, Parkinson's disease, dementia), or head injury with significant loss of consciousness. These exclusion criteria have been applied because they affect brain structure and function.\n* Diagnosis of congestive heart failure\n* Diagnosis of atrial fibrillation or other heart arrhythmia\n* Diagnosis of Chronic obstructive pulmonary disease\n* Diagnosis of cancer (current)\n* History of serious alcohol or drug abuse (past or current)\n* Participants unable to undergo MRI will be excluded. Reasons may include: a. Subjects who have any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.). b. Subjects who have any type of ferromagnetic bioimplant that could potentially be displaced. c. Subjects who have cerebral aneurysm clips. d. Subjects who may have shrapnel imbedded in their bodies (e.g., from war wounds), metal workers and machinists (e.g., potential for metallic fragments in or near the eyes). e. Subjects who are pregnant. Given that the minimum age of recruitment for the current study is 50 years of age, it is unlikely that prospective participants will be excluded because of pregnancy. f. Subjects who have excessive amounts of metal dental work based on records released by their dentist.","60 Years",{"count":49,"type":18},1000,"This study will use an observational cohort to cross-sectionally and longitudinally relate vascular health to clinical, imaging, and biological markers of early Alzheimer's disease and cerebrovascular disease among aging adults. Adjusting for relevant clinical covariates, we will test the hypothesis that vascular health is associated with clinical, brain magnetic resonance imaging (MRI), neuropsychological, and cerebrospinal fluid markers of early cerebrovascular and Alzheimer's disease changes (i.e., prior to the onset of significant cognitive decline or dementia). Secondarily, we will examine medical and genetic factors that might mediate associations between vascular health and brain aging, such as inflammatory processes, insulin resistance, and genetic factors (e.g., APOE, a susceptibility risk factor for dementia). Findings will advance knowledge regarding the role that vascular health plays in brain aging.",[22,52,53,54,55,56,24,25],"Aging","Aged, 80 and Over","Biomarkers","Brain","Case-Control Studies",[58,59,60,61,62,63,64],"Alzheimer's disease","biomarkers","brain MRI","cardiac MRI","mild cognitive impairment","vascular risk factors","longitudinal studies","RECRUITING","2025-08-01",{"date":68,"type":31},"2025-08-06",{"date":70,"type":31},"2012-09-17",{"date":72,"type":18},"2026-12-31",{"name":74,"class":38},"Vanderbilt University Medical Center",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":15,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":39},"100595252","screening-for-cognitive-disorders-in-multiple-sclerosis-100595252","NCT07030036","Screening for Cognitive Disorders in Multiple Sclerosis","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Diagnosed with multiple sclerosis (MS) for at least 6 months according to the 2017 McDonald criteria (SFSEP)\n* Receiving disease-modifying treatment and followed in the neurology day hospital of CH Gonesse\n\nExclusion Criteria:\n\n\\- Under 18 years old","18 Years",{"count":83,"type":18},60,"This study aims to identify cognitive problems in adults with multiple sclerosis (MS). MS can affect memory, thinking speed, and spatial skills, which may impact daily life and work. We will use simple and proven tests to check for these difficulties and see how they affect quality of life. The study will include about 60 patients followed at the neurology day hospital.",[86,24,25,87],"Multiple Sclerosis","Quality of Life","2025-06-12",{"date":90,"type":31},"2025-06-19",{"date":92,"type":18},"2025-07-15",{"date":94,"type":18},"2025-11-15",{"name":37,"class":38},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":15,"minAge":81,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100585468","adaptation-and-normalization-of-a-verbal-episodic-memory-test-in-french-sign-language-100585468","NCT06902753","Adaptation and Normalization of a Verbal Episodic Memory Test in French Sign Language","Adaptation and Normalization of a Verbal Episodic Memory Test (16-item Free and Cued Recall \u002F RL-RI 16) in French Sign Language","RL-RI-LSF","Inclusion Criteria:\n\n* Person aged ≥ 18 yo\n* with severe or profound deafness (hearing loss ≥ 70 decibels)\n* whose main language is French Sign Language\n* able to consent in writing after a clear explanation of the procedure\n* affiliated to the French Healthcare system (Sécurité Sociale) through self or another person\n\nNon-inclusion criteria:\n\n* person with a medical history in neurology (stroke, traumatic brain injury, dementia) or psychiatry bipolar syndrom or schizophrenia that would not be medicated, severe depression)\n* persons with medical developmental backgroung (e.g genetic syndrome)\n* person with cancer history needing chemotherapy\n* person with a diagnosed and untreated sleeping trouble\n* person drinking \\> 10 glasses of alcohol per week or using drugs on a daily basis\n* person with visual issues\n* person under 18yo or unable to take decisions for self\n\nExclusion Criteria:\n\nA score ≤ 20\u002F28 or 17\u002F28 at the MMS-LS test, depending on the schooling of the participant (20\u002F28 for participants with a degree, 17\u002F28 for participants without a degree)",true,{"count":106,"type":18},120,"INTERVENTIONAL",[109],"NA","To date, neuropsychological assessment of deaf signing persons is complicated by a lack of resources, especially the absence of tools available in French Sign Language (LSF). This is due to perceptual and cultural differences, and in particular the linguistic differences between French and LSF.\n\nThis lack of resources significantly hinders access to care for deaf patients, as neuropsychological assessment is often a key clinical criterion in the diagnosis of certain neurological pathologies (Alzheimer's disease in particular) and enables coherent care plans to be drawn up, for example in the aftermath of strokes or traumatic brain injuries.\n\nIn particular, episodic memory (which refers to the ability to memorise information anchored in a specific context) is a cognitive domain that is sensitive to pathologies such as Alzheimer's disease, but it is not currently possible to assess it with deaf signing patients.\n\nThe aim of this study is to create a memory assessment test adapted to a deaf population that expresses in LSF and to normalize this test on this same population.\n\nThe aim is to provide a diagnosis assessment tool, which currently does not exist in France, to improve access to care for deaf people. This project could then be extended to the creation of tests for other cognitive domains (executive functions, attention, social cognition, etc.) and to prospects for cognitive remediation.\n\nThe 16-item Free and Cued Recall test (RL-RI 16) is the best choice because it is easy to use and accurate enough to assess each stage of episodic memory. These qualities make it a decisive tool in certain differential diagnosis.\n\nIn order to select the most relevant signs, lexical lists by frequency in LSF will be drawn up during a preliminary phase, during which the participants will have to give, in one minute, the maximum number of signs belonging to different categories (animals, vegetables, clothes...). These lists will be used to select the most relevant signs according to their frequency (neither too common nor too rare), based on the same principle as RL-RI 16.\n\nIt will then be standardised on deaf adults, for whom LSF is the main language, with no cognitive impairment, across France, via the various Deaf Care Units, with the help of French \u002F LSF interpreters. Working with different centers in France will make it possible to recruit a larger and more representative number of participants, and to be more sensitive to any regional effects.",[25,112,22,113,114,115],"Memory","Deafness","Sign Language","Cognitive Impairment","2025-03-24",{"date":118,"type":31},"2025-03-30",{"date":120,"type":18},"2025-04",{"date":122,"type":18},"2027-04",{"name":124,"class":38},"Poitiers University Hospital",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":133,"conditions":134,"keywords":137,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":39},"100570223","perioperative-il-33-is-associated-with-the-early-stage-of-postoperative-neurocognitive-dysfunction-after-major-abdominal-surgery-100570223","NCT06704451","Perioperative IL-33 is Associated with the Early Stage of Postoperative Neurocognitive Dysfunction After Major Abdominal Surgery","Inclusion Criteria:Patients were included if they had an American Society of Anesthesiologists status of Ⅱto Ⅳ and requiring a Gastrointestinal or a Hepatic surgery .\n\nExclusion Criteria:\n\n1. history of mental diseases;\n2. patients with current Neurological disease;\n3. patients who refused or were unable to finish the neurocognitive evaluation;\n4. preoperative Mini-Mental Stare Examination (MMSE) less than required score (illiteracy \\\u003C17; primary school \\\u003C 20; middle school and higher \\\u003C 24).",{"count":132,"type":18},150,"Perioperative neurocognitive dysfunction(PND) are common complications of major surgery among patients, could be a long-term disease, which sometimes lasts for several years, and it is meaningful to find a biomarker of PND at the early stage.As far as we know, the relationship between IL-33 and PND is not clear yet in the gastrointestinal and hepatic area. Thus, the investigators designed this study to find out the association between IL-33 and occurrence of PND, and determine whether IL-33 could be a biomarker of the early stage of PND.Study population included 150 subjects. Neuropsychological questionnaire were administrated one day before surgery and three days after surgery. And the end of the operation peripheral venous blood was sampled to measure IL-33 inflammatory protein expression in peripheral blood monocytes. Analyze the data and draw conclusions.",[135,24,136,25],"Postoperative Neurocognitive Dysfunction","Postoperative Complications",[138,135,136,139],"Interleukin-33","Inflammasomes","2024-11-24",{"date":142,"type":31},"2024-11-26",{"date":144,"type":31},"2014-08-18",{"date":146,"type":18},"2025-12-30",{"name":148,"class":38},"First Affiliated Hospital of Kunming Medical University"]